[go: up one dir, main page]

BRPI9811031A - processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio. - Google Patents

processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio.

Info

Publication number
BRPI9811031A
BRPI9811031A BRPI9811031A BRPI9811031A BRPI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A BR PI9811031 A BRPI9811031 A BR PI9811031A
Authority
BR
Brazil
Prior art keywords
epo
preparing
human
human epo
gene
Prior art date
Application number
BRPI9811031A
Other languages
English (en)
Inventor
Anne Stern
Michael Brandt
Konrad Honold
Johannes Auer
Hans Koll
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9811031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BRPI9811031A publication Critical patent/BRPI9811031A/pt
Publication of BRPI9811031B1 publication Critical patent/BRPI9811031B1/pt
Publication of BRPI9811031B8 publication Critical patent/BRPI9811031B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção: <b>"preparação de eritropoietina mediante ativação de genes endógeno"<d>. a invenção refere-se a células humanas, que em virtude de uma ativação do gene epo humano endógeno estão em condição, de produzir epo em uma quantidade e pureza suficientes, para possibilitar uma preparação barata de epo humana como preparado farmacêutico. além disso, a invenção refere-se a um processo para preparar tais células produtoras de epo humana, construções de dna para a ativação do gene epo endógeno em células humanas, bem como processos para a produção em escala técnica de epo em células humanas. seqüência de ativação de gene:
BRPI9811031 1997-07-23 1998-07-22 processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmìdio. BRPI9811031B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PCT/EP1998/004590 WO1999005268A1 (de) 1997-07-23 1998-07-22 Herstellung von erythropoietin durch endogene genaktivierung

Publications (3)

Publication Number Publication Date
BRPI9811031A true BRPI9811031A (pt) 2000-08-08
BRPI9811031B1 BRPI9811031B1 (pt) 2011-10-04
BRPI9811031B8 BRPI9811031B8 (pt) 2021-07-06

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811031 BRPI9811031B8 (pt) 1997-07-23 1998-07-22 processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmìdio.

Country Status (13)

Country Link
EP (1) EP0986644B1 (pt)
JP (1) JP4541539B2 (pt)
CN (1) CN1151258C (pt)
AT (1) ATE341625T1 (pt)
AU (1) AU754619B2 (pt)
BR (1) BRPI9811031B8 (pt)
CA (1) CA2298015C (pt)
DE (1) DE59813758D1 (pt)
DK (1) DK0986644T3 (pt)
ES (1) ES2273434T3 (pt)
TR (1) TR200000175T2 (pt)
TW (1) TW574372B (pt)
WO (1) WO1999005268A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AR022358A1 (es) 1997-12-03 2002-09-04 Roche Olivier Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
NZ548578A (en) 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (ko) * 2001-10-30 2005-06-02 신풍제약주식회사 동물세포용 재조합 벡터 및 에리트로포이에틴을 대량으로 생산하기 위한 동물세포용 발현벡터
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2002357019A1 (en) 2001-11-28 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
JP4865539B2 (ja) 2003-05-09 2012-02-01 クルセル ホランド ベー ヴェー Ｅ１不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PT1974014T (pt) 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
WO2008112703A2 (en) * 2007-03-12 2008-09-18 University Of Utah Research Foundation Compositions and methods for diagnosing and treating diabetic micro vascular complications
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CA2736141C (en) 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
CN102659928B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659927B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN104059128B (zh) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (ja) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd 組換えヒトエリスロポエチンの精製方法
AU635844B2 (en) * 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0505500T3 (da) * 1989-12-22 1997-08-25 Applied Research Systems Modificering af endogen genekspression med regulatorisk element ved hjælp af homolog rekombination
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
ATE341625T1 (de) 2006-10-15
AU8978698A (en) 1999-02-16
BRPI9811031B1 (pt) 2011-10-04
DE59813758D1 (de) 2006-11-16
ES2273434T3 (es) 2007-05-01
EP0986644B1 (de) 2006-10-04
TW574372B (en) 2004-02-01
CA2298015A1 (en) 1999-02-04
JP2001511343A (ja) 2001-08-14
JP4541539B2 (ja) 2010-09-08
DK0986644T3 (da) 2007-01-29
WO1999005268A1 (de) 1999-02-04
TR200000175T2 (tr) 2001-01-22
CA2298015C (en) 2015-01-27
CN1151258C (zh) 2004-05-26
AU754619B2 (en) 2002-11-21
CN1265143A (zh) 2000-08-30
EP0986644A1 (de) 2000-03-22
BRPI9811031B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
BRPI9811031A (pt) processo para preparar uma célula produtora de epo humana, processo para preparar epo humana, construção de dna para ativação de gene de epo endógeno, bem como plasmídio.
HUP9801697A2 (hu) Új protein és eljárás előállítására
PT2302063T (pt) Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
EP1211310A4 (en) NOVEL YEAST VARIANTS AND PROCESS FOR THE PRODUCTION OF GLYCOPROTEIN
EP1095158A4 (en) METHOD AND MATERIALS FOR THE PRODUCTION OF GLUCOSAMINE
ATE405644T1 (de) Verfahren zur herstellung und reinigung von erythropoietin
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
MX9304027A (es) Variante de al enzima lipasa y metodo para su produccion.
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BR0012712B1 (pt) métodos de produção de l-aminoácidos aumentando-se o nadph celular.
MX2010003644A (es) Ensamble de acidos nucleicos grandes.
BR9913360A (pt) Oxidase de urato
DK64990D0 (da) Kunstigt gen, som koder for autentisk humant serumalbumin, fremgangsmaade til fremstilling deraf, rekombinant-dna-molekyle indeholdende genet, vaertsorganisme transformeret dermed, fremgangsmaade til fremstilling af autentisk humant serumalbumin og farmaceutisk praeparat indeholdende saaledes fremstillet serumalbumin
BR112023008361A2 (pt) Variantes de glucoamilase e polinucleotídeos codificando as mesmas
ATE314389T1 (de) Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor
BR9813099A (pt) Seleção positiva-negativa na recombinação homóloga
BR9811542A (pt) Identificação de linhas de células humanas para a produção de proteìnas humanas mediante ativação de genes endógena
BR0211066A (pt) produção de células progenitoras hematopoiéticas transduzidas
WO2002098455A8 (en) Production of recombinant human arylsulfatase a
DE69939876D1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren
PT1058739E (pt) Metodo para produzir perfis de expressao genica
ID26784A (id) Pembuatan sel-sel untuk memproduksi yang perhubungan dengan biologi
DE69837047D1 (de) Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen
DE50110507D1 (de) Verfahren in vitro zum einbringen von nukleinsäure in eine zelle (transfektion) mittels calciumphosphat
TR200700154A2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.07.2018